---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Cost-effectiveness evidence"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Cost-effectiveness evidence. Topics: Summary: ICER assessment, other published economic evaluations, and commercial forecasts; ICER assessment status; ICER evidence ratings; ICER cost-effectiveness model: structure, perspective, and populations; 19 further topics. 23 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics/cost-effectiveness"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: ICER assessment, other published economic evaluations, and commercial forecasts

The Institute for Clinical and Economic Review (ICER) assessed baxdrostat and lorundrostat for hypertension in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and ICER's meeting slides state that the final report would be published “on or around November 30, 2026”. ICER rated the evidence for lorundrostat or baxdrostat compared with spironolactone, eplerenone, or amiloride as “Promising but Inconclusive” in participants with resistant hypertension or intolerance of a third first-line drug (Populations 1 and 2), as “comparable or inferior” to amlodipine in participants not yet treated with a third drug (Population 3), and as insufficient to distinguish lorundrostat from baxdrostat. ICER's lifetime model used the 50 mg once-daily dose of lorundrostat and a placeholder price equal to the baxdrostat wholesale acquisition cost ($10,950 per year). At that price, lorundrostat cost $1,419,000 per QALY gained compared with spironolactone and $1,492,000 compared with amiloride, and was “More costly, less effective” than eplerenone, which ICER attributed to a 10% first-cycle discontinuation probability for lorundrostat against 7.7% for eplerenone. Lorundrostat was cost-effective in 0.0% of probabilistic simulations at $150,000 per evLY gained, and the health-benefit price benchmark for lorundrostat was $760 to $1,600 per year (85.7% to 93.0% below the placeholder price), against $1,400 to $2,500 per year for baxdrostat. Mineralys commented that the model “does not fully capture the clinical and economic benefits of ASIs”, that first-cycle discontinuation of lorundrostat (10%) was based on Launch-HTN and that of eplerenone and amiloride (7.7%) on a study of Swedish patients receiving calcium channel blockers, and that models should incorporate dynamic pricing; a commenting coalition, No Patient Left Behind, estimated a societal value-based price of $18,767 to $26,913 per year. A 2026 review states that cost-effectiveness evidence for aldosterone synthase inhibitors is still needed. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified; a 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, 12 of 14 cost-utility analyses evaluating renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective), $12,900 per QALY for ultrasound renal denervation, $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY for team-based care with non-physician titration, and cost savings of $10,162 per person for pharmacist prescribing. No sales forecast from Mineralys was identified; GlobalData forecast lorundrostat sales of $601 million in 2030, and Visible Alpha consensus projected risk-adjusted sales of $122 million in 2027 and $365 million in 2028, with analysts expecting annual revenue of $1.1 billion by 2030.

Source: [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/); [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf); [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/); [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/); [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/); [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/); [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/); [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/); [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/); [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/); [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)

<a id="topic-4.1-2"></a>

### ICER assessment status

> “An assessment of baxdrostat and lorundrostat”
> “Final Evidence Report and Meeting Summary”
> “The Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension:”

Source: [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/)

> “Final Report published on or around November 30, 2026”
> “Includes description of Midwest CEPAC votes, deliberation, policy roundtable discussion”

Source: [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf)

<a id="topic-4.1-3"></a>

### ICER evidence ratings

> “Our analyses of currently available data did not show differences in effect between ASIs; thus, for all three populations, current data are “insufficient” (I) to determine the net health benefits of baxdrostat and lorundrostat compared with each other.”
> “For patients with resistant hypertension not at goal and those on two antihypertensive medications who did not tolerate a third first-line treatment (Populations 1 and 2), our analyses found no statistically significant difference in blood pressure lowering between all agents. However, ASIs such as baxdrostat and lorundrostat may be better tolerated than spironolactone and may result in greater blood pressure reductions than comparator drugs, though trials are only short-term. Thus, for these Populations, we conclude that the net health benefits of baxdrostat or lorundrostat are “Promising but Inconclusive” (P/I) compared with spironolactone, eplerenone, or amiloride.”
> “In the absence of convincing outcomes data with the ASIs, we feel that, compared with amlodipine, the net health benefit of baxdrostat or lorundrostat is “comparable or inferior” (C-).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-4"></a>

### ICER cost-effectiveness model: structure, perspective, and populations

> “We developed a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models”
> “Costs and outcomes were discounted at 3% per year. Model cycle length was three months. The analysis was conducted from a US health care sector perspective over a lifetime time horizon.”
> “Populations 1 and 2 were therefore reduced to a single modeled population. Population 3 was not modeled as the comparative effectiveness review rated baxdrostat and lorundrostat as “comparable or inferior” to amlodipine and, consistent with the Model Analysis Plan, cost-effectiveness in this population was to be evaluated only if the aldosterone synthase inhibitors were superior to amlodipine.”
> “As shown in Figure 4.1, the model included seven primary health states: 1) hypertension alone, 2) stroke, 3) myocardial infarction (MI), 4) other symptomatic coronary heart disease (CHD), 5) heart failure (HF), 6) end-stage kidney disease (ESKD), and 7) death.”
> “Baseline characteristics were informed by the Bax24, BaxHTN, and Launch-HTN clinical trials”
> “For each intervention we modeled the dose most likely to be used in clinical practice, namely the 50 mg dose for lorundrostat and the 2 mg dose for baxdrostat, both administered as once daily tablets.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-5"></a>

### ICER cost-effectiveness model: treatment effect inputs

> “Each treatment’s effect was estimated and modeled through its SBP reduction from ICER’s internal NMA (Table 4.2).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Parameter | Quoted input |
| --- | --- |
| SBP reduction for lorundrostat vs. placebo (mm Hg) | “9.0, (95% CrI: 1.7, 16.4)” |
| SBP reduction for baxdrostat vs. placebo (mm Hg) | “11.0 (95% CrI: 7.3, 14.6)” |
| SBP reduction for spironolactone vs. placebo (mm Hg) | “10.1 (95% CrI: 6.7, 13.1)” |
| SBP reduction for eplerenone vs. placebo (mm Hg) | “8.8 (95% CrI: 2.3, 15.5)” |
| SBP reduction for amiloride vs. placebo (mm Hg) | “6.6 (95% CrI: 1.4, 11.6)” |
| Hazard ratio for stroke, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.84, 0.91)” |
| Hazard ratio for ischemic heart disease, per 5 mm Hg SBP reduction | “0.92 (95% CI: 0.89, 0.95)” |
| Hazard ratio for heart failure, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.83, 0.92)” |
| Relative risk for ESKD, per 10 mm Hg SBP reduction | “0.95 (95% CI: 0.84, 1.07)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-6"></a>

### ICER cost-effectiveness model: base-case results at the placeholder price

> “Over a lifetime horizon, treatment with baxdrostat led to small evLY, QALY, and LY gains compared to the three comparators. Treatment with lorundrostat led to similar gains, except compared to eplerenone, where eplerenone had slightly better outcomes at a lower cost.”
> “lorundrostat was modelled with higher discontinuation probability after three months or one cycle (10% based on Launch-HTN) than eplerenone (7.7% from the literature-based persistence curve), which made it less effective and more costly than eplerenone in the base case.”
> “Compared to the comparators, the total costs were higher for baxdrostat and lorundrostat, driven primarily by the higher drug costs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Treatment | Intervention acquisition costs | Non-intervention costs | Total costs | QALYs | evLYs | LYs |
| --- | --- | --- | --- | --- | --- | --- |
| Lorundrostat (placeholder price) | “$28,500” | “$122,200” | “$150,700” | “9.54” | “9.54” | “11.86” |
| Baxdrostat | “$27,600” | “$122,000” | “$149,600” | “9.55” | “9.55” | “11.87” |
| Spironolactone | “$200” | “$122,600” | “$122,800” | “9.52” | “9.52” | “11.83” |
| Eplerenone | “$2,000” | “$122,200” | “$124,300” | “9.54” | “9.54” | “11.86” |
| Amiloride | “$830” | “$122,500” | “$123,400” | “9.52” | “9.52” | “11.84” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Treatment and comparator | Cost per QALY gained | Cost per evLY gained | Cost per life year gained |
| --- | --- | --- | --- |
| Lorundrostat (placeholder price) vs. spironolactone | “$1,419,000” | “$1,327,000” | “$1,213,000” |
| Lorundrostat (placeholder price) vs. eplerenone | “More costly, less effective” | “More costly, less effective” | “More costly, less effective” |
| Lorundrostat (placeholder price) vs. amiloride | “$1,492,000” | “$1,403,000” | “$1,273,000” |
| Baxdrostat vs. spironolactone | “$833,000” | “$781,000” | “$712,000” |
| Baxdrostat vs. eplerenone | “$2,077,000” | “$1,954,000” | “$1,774,000” |
| Baxdrostat vs. amiloride | “$851,000” | “$800,000” | “$727,000” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-7"></a>

### ICER cost-effectiveness model: sensitivity and probabilistic analyses

> “For lorundrostat, the range of incremental evLYs gained crossed zero when its SBP reduction was varied.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Lorundrostat (placeholder price) compared with | Cost-effective at $50,000 per evLY gained | Cost-effective at $100,000 per evLY gained | Cost-effective at $150,000 per evLY gained | Cost-effective at $200,000 per evLY gained |
| --- | --- | --- | --- | --- |
| Spironolactone | “0.0%” | “0.0%” | “0.0%” | “0.0%” |
| Eplerenone | “0.0%” | “0.0%” | “0.0%” | “0.2%” |
| Amiloride | “0.0%” | “0.0%” | “0.0%” | “0.2%” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-8"></a>

### ICER cost-effectiveness model: scenario analyses

> “While the incremental cost-effectiveness ratios improved slightly in the modified societal and the same treatment discontinuation scenarios, they were still well above commonly accepted threshold ranges.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Scenario (cost per QALY gained, lorundrostat at the placeholder price) | Compared with spironolactone | Compared with eplerenone | Compared with amiloride |
| --- | --- | --- | --- |
| Modified societal perspective | “$1,404,000” | “Lower effect, higher cost” | “$1,479,000” |
| Same discontinuation for all treatments | “$1,322,000” | “$16,455,000” | “$1,382,000” |
| No discontinuation for all treatments | “Lower effect, higher cost” | “$16,956,000” | “$1,436,000” |
| 10-year treatment effect duration | “$1,698,000” | “Lower effect, higher cost” | “$1,577,000” |
| 20-year treatment effect duration | “$1,437,000” | “Lower effect, higher cost” | “$1,498,000” |
| 5-year time horizon | “$28,854,000” | “$166,418,000” | “$10,593,000” |
| 10-year time horizon | “$5,392,000” | “$123,253,000” | “$3,622,000” |
| Minimum price for generic comparators | “$1,428,000” | “Lower effect, higher cost” | “$1,521,000” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-9"></a>

### ICER health-benefit price benchmark and threshold prices

> “The Health Benefit Price Benchmark (HBPB) for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between $100,000 per QALY gained and $150,000 per evLY gained. The HBPB for baxdrostat is $1,400 to $2,500 per year and for lorundrostat is $760 to $1,600 per year.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Intervention and outcome measure | Annual WAC | Annual price at $100,000 threshold | Annual price at $150,000 threshold | Discount from WAC to reach threshold prices |
| --- | --- | --- | --- | --- |
| Lorundrostat, QALYs gained (placeholder price) | “$10,950” | “$760” | “$1,500” | “86.3% - 93.0%” |
| Lorundrostat, evLYs gained (placeholder price) | “$10,950” | “$770” | “$1,600” | “85.7% - 93.0%” |
| Baxdrostat, QALYs gained | “$10,950” | “$1,400” | “$2,400” | “78.3% - 87.4%” |
| Baxdrostat, evLYs gained | “$10,950” | “$1,400” | “$2,500” | “77.2% - 87.1%” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Lorundrostat compared with (QALY-based) | Annual price to achieve $50,000 per QALY gained | Annual price to achieve $100,000 per QALY gained | Annual price to achieve $150,000 per QALY gained | Annual price to achieve $200,000 per QALY gained |
| --- | --- | --- | --- | --- |
| Spironolactone | “$600” | “$980” | “$1,400” | “$1,700” |
| Eplerenone | “$770” | “$770” | “$760” | “$760” |
| Amiloride | “$790” | “$1,100” | “$1,500” | “$1,900” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-10"></a>

### ICER cost-effectiveness model: limitations and conclusion

> “SBP reductions for each treatment were estimated from ICER’s internal NMA rather than from head-to-head trials. Because these estimates relied on indirect comparisons rather than head-to-head evidence, several treatment effects, particularly lorundrostat, eplerenone, and amiloride, had wide credible intervals, representing uncertainty in the relative treatment effects that drove the cost-effectiveness results.”
> “The baxdrostat and lorundrostat trials measured SBP reductions rather than cardiovascular and kidney events. The model translated these reductions into changes in event risk using HRs and RR from the BPLTTC meta-analysis. The assumption that this SBP to event relationship applies to aldosterone synthase inhibitors is not confirmed.”
> “At their current WAC-based price and placeholder price, the incremental cost-effectiveness ratios for baxdrostat and lorundrostat were well above commonly used cost-effectiveness thresholds.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-11"></a>

### ICER comparison with prior economic models

> “These projections were consistent with comparable US cost-effectiveness analyses of hypertension conducted over a lifetime horizon at a 3% discount rate.”
> “Geisler et al. (2012) was the original model that used this assessment’s model schematic in a population of resistant hypertension, and they reported a median survival of 17.1 years for standard of care with a cohort entering their model at 58 years old”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-12"></a>

### Manufacturer comments on the ICER draft evidence report

> “ICER’s economic model does not fully capture the clinical and economic benefits of ASIs for patients with HTN.”
> “Mineralys strongly recommends that ICER remove amiloride and eplerenone as comparators in this review.”
> “In the base-case analysis, discontinuation of lorundrostat in the first three months is estimated to be 10% based on data from Launch-HTN, whereas the discontinuation rate of eplerenone and amiloride was 7.7%, based on a real-world study that examined Swedish patients receiving calcium channel blockers.”
> “As ASIs are subject to price declines due to market dynamics and eventual genericization, models should incorporate dynamic pricing, rather than constant lifetime pricing, to avoid overstating long-term costs.”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

<a id="topic-4.1-13"></a>

### ICER responses to the manufacturer comments

> “We selected our source study because it aligned well with the disease status of our patient population and provided sufficient data to construct a discontinuation function.”
> “Finally, we tested several scenarios around our discontinuation assumption, and none changed our conclusion.”
> “Consistent with best practices in HTA, ICER does not as a rule consider “dynamic pricing” in economic evaluation unless there is known timing for patent expiry and certainty around expected changes in price (both during the period of patent protection and following generic entry).”

Source: [ICER response to public comments (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public_Comment_Grid-For-Publication-102626.pdf)

<a id="topic-4.1-14"></a>

### Stakeholder exploratory analyses of dynamic pricing and societal value

> “No Patient Left Behind (NPLB) is a nonprofit coalition of biotechnology innovators, investors, healthcare professionals, economists, and patient advocates working to ensure that patients have access to the medicines they need today and in the future.”
> “Adjusting these two assumptions alone moved the published ratios by 30–48% in the base case and up to 70% under ICER's own no-discontinuation scenario.”
> “The findings suggest that the societal value-based price for lorundrostat ranges from $18,767 per year (base case) to $26,913 per year (optimistic case).”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

<a id="topic-4.1-15"></a>

### Published cost-effectiveness analyses of lorundrostat other than the ICER assessment

No evidence found.

<a id="topic-4.1-16"></a>

### Cost-effectiveness evidence needed for aldosterone synthase inhibitors

> “The ASIs represent a promising class of antihypertensive drug classes with proven efficacy in reducing both office and ambulatory blood pressure, although studies on their comparative efficacy and safety with MRAs such as spironolactone are needed, along with evidence of cost-effectiveness.”

Source: [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/)

<a id="topic-4.1-17"></a>

### Published cost-effectiveness analyses of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension

No evidence found.

<a id="topic-4.1-18"></a>

### Systematic review of economic models in treatment-resistant and uncontrolled hypertension

> “A total of 21 modelling studies were included: 16 economic evaluations (14 cost-utility analyses, 1 cost-effectiveness analysis and 1 cost-minimization analysis), 4 burden-of-illness studies and 1 budget impact analysis.”
> “Of the 14 CUAs, 12 evaluated RDN: of these, 7 evaluations comparing radio frequency (RF) RDN plus standard of care (SoC) to SoC alone in different healthcare settings were based on the same model”
> “Although models were generally assessed to be of good quality, models incorporated health-related quality of life and cost data from controlled hypertensive or non-hypertensive populations, rather than those with ucHTN and trHTN.”

Source: [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/)

<a id="topic-4.1-19"></a>

### Radiofrequency renal denervation, United States Medicare payer perspective

> “A decision-analytic Markov model projected costs, quality-adjusted life years (QALY), and clinical events for an active cohort treated with RF RDN and a control cohort treated with standard-of-care (defined as 1, 2, or 3 antihypertensive medications).”
> “The model projected costs and effects with a lifetime horizon from a Medicare payer perspective.”
> “Over lifetime, RF RDN added 0.34 QALY at an additional cost of $11,275, leading to an incremental cost-effectiveness ratio of $32,732 per QALY.”

Source: [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/)

<a id="topic-4.1-20"></a>

### Ultrasound renal denervation, United States health care system perspective

> “A previously published Markov model was adapted to compare total costs and quality-adjusted life years (QALY) between uRDN plus standard of care (SoC) vs SoC alone over a lifetime horizon from a US health care system perspective.”
> “Using a procedure cost of $23,000, total lifetime costs were higher with the uRDN procedure (uRDN plus SoC: $110,476 vs SoC alone: $102,875), resulting in an incremental cost-effectiveness ratio of $12,900 per QALY.”

Source: [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/)

<a id="topic-4.1-21"></a>

### Catheter-based renal denervation for resistant hypertension, first United States model

> “We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in U.S. dollars per quality-adjusted life-year, both discounted at 3% per year.”
> “The discounted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year.”

Source: [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/)

<a id="topic-4.1-22"></a>

### Team-based care with non-physician medication titration, United States

> “Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.”

Source: [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/)

<a id="topic-4.1-23"></a>

### Pharmacist prescribing for hypertension, United States

> “The intervention was also associated with 0.34 (2.5th-97.5th percentiles, 0.23-0.45) additional life years and 0.62 (2.5th-97.5th percentiles, 0.53-0.73) additional QALYs.”
> “The cost savings were $10 162 (2.5th-97.5th percentiles, $6636-$13 581) per person due to fewer CV events with the pharmacist-prescribing intervention, even after the cost of the visits and medication adjustments.”

Source: [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-4.1-24"></a>

### Forecast sales of lorundrostat

> “According to GlobalData forecasts, sales of lorundrostat could reach $601m in 2030.”

Source: [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/)

> “Visible Alpha consensus assigns lorundrostat a 90% probability of US approval in the indication, with risk-adjusted sales projected at $122 million in 2027, pending approval, and $365 million in 2028. Analysts expect the drug to reach blockbuster status by 2030, with annual revenue of $1.1 billion.”
> “Visible Alpha consensus reflects that advantage, with Baxfendy projected to establish a clear lead in the ASI market and generate substantially higher sales than lorundrostat over the remainder of the decade.”

Source: [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)

<a id="topic-4.1-25"></a>

### Manufacturer statements on the market opportunity

> “Over 30 million hypertensive patients in the United States are unable to achieve their BP goal despite treatment, and within this population, 10 million suffer from rHTN”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “we clearly see a significant market opportunity here with, as we stated before, about 20 million patients in the United States alone dealing with uncontrolled and resistant hypertension.”
> “There is certainly room for two novel therapeutics in what I think may be a transformative class overall.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
